KR20100090514A - Food composition for accelerating the growth - Google Patents
Food composition for accelerating the growth Download PDFInfo
- Publication number
- KR20100090514A KR20100090514A KR1020090009842A KR20090009842A KR20100090514A KR 20100090514 A KR20100090514 A KR 20100090514A KR 1020090009842 A KR1020090009842 A KR 1020090009842A KR 20090009842 A KR20090009842 A KR 20090009842A KR 20100090514 A KR20100090514 A KR 20100090514A
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- parts
- extract
- growth
- antler
- Prior art date
Links
- 230000012010 growth Effects 0.000 title claims abstract description 31
- 235000013305 food Nutrition 0.000 title claims abstract description 23
- 239000000203 mixture Substances 0.000 title claims abstract description 22
- 239000000284 extract Substances 0.000 claims abstract description 44
- 235000006533 astragalus Nutrition 0.000 claims abstract description 11
- 230000001737 promoting effect Effects 0.000 claims abstract description 9
- 210000003056 antler Anatomy 0.000 claims description 25
- 210000004207 dermis Anatomy 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 10
- 241000125175 Angelica Species 0.000 claims description 9
- 241001061264 Astragalus Species 0.000 claims description 9
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 9
- 210000004233 talus Anatomy 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 241000194110 Bacillus sp. (in: Bacteria) Species 0.000 claims description 5
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 4
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 claims description 4
- 235000019206 astragalus extract Nutrition 0.000 claims description 4
- 235000020717 hawthorn extract Nutrition 0.000 claims description 4
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims description 3
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims description 3
- 235000009685 Crataegus X maligna Nutrition 0.000 claims description 3
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims description 3
- 235000009486 Crataegus bullatus Nutrition 0.000 claims description 3
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims description 3
- 235000009682 Crataegus limnophila Nutrition 0.000 claims description 3
- 235000004423 Crataegus monogyna Nutrition 0.000 claims description 3
- 235000002313 Crataegus paludosa Nutrition 0.000 claims description 3
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims description 3
- 240000000171 Crataegus monogyna Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 11
- 241000045403 Astragalus propinquus Species 0.000 abstract description 2
- 235000017159 Crataegus pinnatifida Nutrition 0.000 abstract description 2
- 241000657480 Crataegus pinnatifida Species 0.000 abstract description 2
- 235000008216 herbs Nutrition 0.000 abstract 2
- 241000382455 Angelica sinensis Species 0.000 abstract 1
- 241000092665 Atractylodes macrocephala Species 0.000 abstract 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 abstract 1
- 210000004349 growth plate Anatomy 0.000 description 31
- 239000012676 herbal extract Substances 0.000 description 28
- 241000700159 Rattus Species 0.000 description 17
- 210000000988 bone and bone Anatomy 0.000 description 14
- 238000000855 fermentation Methods 0.000 description 10
- 230000004151 fermentation Effects 0.000 description 10
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 9
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 9
- 210000001612 chondrocyte Anatomy 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 7
- 230000008859 change Effects 0.000 description 5
- 230000008468 bone growth Effects 0.000 description 4
- 238000002073 fluorescence micrograph Methods 0.000 description 4
- 238000012744 immunostaining Methods 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 230000011164 ossification Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 241000282994 Cervidae Species 0.000 description 3
- 102000018997 Growth Hormone Human genes 0.000 description 3
- 108010051696 Growth Hormone Proteins 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 208000037824 growth disorder Diseases 0.000 description 3
- 239000000122 growth hormone Substances 0.000 description 3
- 235000021590 normal diet Nutrition 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 210000002303 tibia Anatomy 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 241001092040 Crataegus Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000000921 morphogenic effect Effects 0.000 description 2
- 229960002378 oftasceine Drugs 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 241000132011 Atractylodes lancea Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical group [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 241000675108 Citrus tangerina Species 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010024604 Lipoatrophy Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 244000197580 Poria cocos Species 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000612118 Samolus valerandi Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- ZHAFUINZIZIXFC-UHFFFAOYSA-N [9-(dimethylamino)-10-methylbenzo[a]phenoxazin-5-ylidene]azanium;chloride Chemical compound [Cl-].O1C2=CC(=[NH2+])C3=CC=CC=C3C2=NC2=C1C=C(N(C)C)C(C)=C2 ZHAFUINZIZIXFC-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000003321 cartilage cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000013522 chelant Chemical group 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000000459 effect on growth Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/70—Clarifying or fining of non-alcoholic beverages; Removing unwanted matter
- A23L2/72—Clarifying or fining of non-alcoholic beverages; Removing unwanted matter by filtration
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
- A23L5/51—Concentration
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/204—Animal extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/24—Heat, thermal treatment
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/31—Mechanical treatment
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/50—Concentrating, enriching or enhancing in functional factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/07—Bacillus
Abstract
Description
본 발명은 성장 촉진 효과를 제공하는 식품 조성물에 관한 것이다.The present invention relates to a food composition that provides a growth promoting effect.
소아의 성장이란 단순히 신장이 증가하는 것뿐만 아니라 신체 각 기관의 해부학적, 형태학적 크기와 기능이 증가하는 것, 즉 기능의 발달 및 기관으로의 분화를 모두 의미한다.Growth in children means not only an increase in height, but also an increase in the anatomical and morphological size and function of each organ, ie the development of function and differentiation into organs.
최근, 지속적인 경제 성장과 식습관의 서구화, 영양상태의 개선 등으로 인해 소아 및 청소년의 성장발육이 크게 증가되는 추세이다. 또한 매스미디어를 통해 큰 키를 선호하는 사회적 분위기가 형성됨으로써 상대적으로 신장이 작은 소아의 열등감이 가중되어 왔다. 이렇게 평균 신장이 늘어남에 따라 대부분의 사람들이 성장에 많은 관심을 갖게 되었다.Recently, the growth and development of children and adolescents has been greatly increased due to continuous economic growth, westernization of eating habits, and improvement of nutritional status. In addition, mass media have created a social atmosphere that favors taller heights, which has resulted in an increase in inferiority in children with smaller heights. As the average height increases, most people are interested in growth.
알려진 성장장애 치료법에는 성장 호르몬 제제 투여, 일리자로프 수술 등이 있다. 성장 호르몬 사용에 의한 성장장애 치료의 경우, 성장과 관련된 여러가지 인자들을 함께 고려해야 하고, 주사부위의 소양감, 발작, 지방위축과 고혈압, 당 불 내성(glucose intolerance), 췌장염, 전신 알레르기 반응, 성장 호르몬 항체 양성, 암 발생 및 남성에게 여성화 유방 등의 증상과 같은 부작용이 있을 수 있다. 또한, 일리자로프 수술 요법에 의한 성장장애 치료의 경우, 키가 작은 사람이 양쪽다리를 모두 억지로 늘리기 위해 수술 요법을 사용하는 것으로, 환자의 고통이 클 수 있으며, 많은 비용이 소요될 뿐만 아니라 예상치 못한 부작용으로 인해 정상보행을 못할 수도 있다.Known treatments for growth disorders include the administration of growth hormone preparations, and ilizarov surgery. In the case of treatment of growth disorders by the use of growth hormone, various factors related to growth should be taken into account, along with pruritus, seizures, fat atrophy and hypertension, glucose intolerance, pancreatitis, systemic allergic reactions, and growth hormone antibodies. There may be side effects such as benign, cancer development, and symptoms such as feminized breast. In addition, in the treatment of growth disorders by ilizarov surgical therapy, the use of surgical therapy to forcibly lengthen both legs by a short person can be painful, expensive, and unexpected. Side effects may prevent you from walking normally.
따라서, 성장에 근본적으로 도움을 줄 수 있는, 과학적으로 검증된 의약품 및 식품소재에 대한 개발이 절실히 필요한 실정이다.Therefore, there is an urgent need for the development of scientifically-proven drugs and foodstuffs that can fundamentally help growth.
따라서, 본 발명의 목적은 부작용 없이 우수한 성장 촉진 효과를 가져올 수 있는 식품 조성물을 제공하는 것이다.Accordingly, it is an object of the present invention to provide a food composition which can bring about an excellent growth promoting effect without side effects.
이에 본 발명에서는 황기, 백출, 백복령, 진피, 맥아, 당귀, 산사 및 녹용 각각의 추출물을 포함하는 성장 촉진용 식품 조성물을 제공한다. Therefore, the present invention provides a food composition for growth promotion comprising extracts of Astragalus, Baekchul, Baekbokyeong, Dermis, Malt, Angelica, Sansa and Deer Antler.
상기 식품 조성물은 상기 녹용 추출물 100중량부를 기준으로, 상기 황기 추출물 10 내지 50중량부, 상기 백출 추출물 5 내지 45중량부, 상기 백복령 추출물 5 내지 45중량부, 상기 진피 추출물 5 내지 45중량부, 상기 맥아 추출물 5 내지 45중 량부, 상기 당귀 추출물 5 내지 45중량부, 및 상기 산사 추출물 5 내지 45중량부를 포함할 수 있다.The food composition is based on 100 parts by weight of the antler extract, 10 to 50 parts by weight of the Astragalus extract, 5 to 45 parts by weight of the white extract, 5 to 45 parts by weight of the Baekbokyeong extract, 5 to 45 parts by weight of the dermis extract, 5 to 45 parts by weight of the malt extract, 5 to 45 parts by weight of the Angelica extract, and 5 to 45 parts by weight of the hawthorn extract.
이때, 상기 황기, 상기 백출, 상기 백복령, 상기 진피, 상기 맥아, 상기 당귀, 상기 산사 및 상기 녹용의 추출물은 열수 추출물일 수 있다.At this time, the extract of the Astragalus, the Baekchul, the Baekbokryeong, the dermis, the malt, the Angelica, the hawthorn and the antler may be a hydrothermal extract.
또한, 상기 식품 조성물에 있어서, 상기 녹용 추출물은 바실러스 속 (Bacillus sp.) 균주로 발효된 것일 수 있으며, 이는 바실러스 속 균주로 발효된 녹용을 추출하여 얻은 것이거나 녹용을 추출한 후 이를 바실러스 속 균주로 발효시켜 얻은 것일 수 있다.In addition, in the food composition, the antler extract may be fermented with Bacillus sp. Strain, which is obtained by extracting the antler fermented with the Bacillus sp. Strain or after extracting the antler to the strain of Bacillus sp. It may be obtained by fermentation.
본 발명에 따른 식품 조성물은 뼈 길이를 성장시키고, 성장판 연골세포의 대사를 촉진하고, 성장인자인 IGF-1(인슐린양 성장인자(insulin-like growth factor)-1) 및 BMP-2(골 형성 단백질(bone morphogenic protein)-2)의 발현을 증가시키는 등 부작용 없이 우수한 성장 촉진 효과를 가져올 수 있어 특히 어린이 성장 촉진용 식품소재로서 유용하게 사용될 수 있다.Food composition according to the present invention is to increase the bone length, promote the metabolism of growth plate chondrocytes, growth factors IGF-1 (insulin-like growth factor-1) and BMP-2 (bone formation Protein (bone morphogenic protein) -2) can bring about excellent growth promoting effect without side effects, such as increasing the expression of it can be particularly useful as a food material for promoting children's growth.
본 발명의 일 실시예에 따른 성장 촉진용 식품 조성물은 황기, 백출, 백복령, 진피, 맥아 , 당귀, 산사, 및 녹용과 같은 생약재의 추출물을 필수 성분으로서 포함한다.The food composition for promoting growth according to an embodiment of the present invention includes extracts of herbal medicines such as Astragalus, Baekchul, Baekbokyeong, Dermis, Malt, Angelica, Sansa, and Deer Antler as essential ingredients.
황기(학명: Astragalus membranaceus Bunge var. membranaceus)는 콩과에 속하는 다년생 초본식물이나, 이 풀의 뿌리를 캐어 껍질을 벗기고 말린 것을 보통 황기라 한다. 뿌리는 길이가 80∼100cm 가량 되는 것도 있을 정도로 대단히 길다. Astragalus membranaceus Bunge var.membranaceus is a perennial herbaceous plant belonging to the legume, or the root of the grass is peeled and dried. Roots are very long, some 80-100 cm long.
백출은 삽주(학명: Atractylodes ovata (Thunb.) DC.)의 덩이줄기를 말린 약재로서, 맛은 달고 쓰며 성질은 따뜻한데, 비기를 보하고 입맛을 돕고 음식물의 소화를 도우며 이뇨 작용을 하는 것으로 알려져 있다.Baekchul is a dried medicinal herb of the shovel (Atractylodes ovata (Thunb.) DC. ), Tastes sweet and bitter and warm in nature. have.
백복령은 빛깔이 흰 복령(학명: Poria cocos (Schw) wolf)으로서, 복령은 소나무를 벌채한 뒤 3∼10년 후 뿌리에 기생하여 성장하는 균핵으로 형체가 일정하지 않다. 백복령은 오줌이 잘 나오게 하고 담병, 부종(浮腫), 습증 따위를 다스리거나 몸을 보하는 데 쓰이는 것으로 알려져 있다.Baekbok-ryeong is a white-colored Bokryeong (People's name: Poria cocos (Schw) wolf ), which is a fungal nucleus that grows in roots 3-10 years after logging pine trees. Baekbokryeong is known to be used to urinate well and to control or protect the body, such as biliary edema, swelling and dampness.
진피(陳皮)는 운향과의 귤(학명: Citrus unshiu Markovich) 또는 동속 근연식물의 성숙한 과피를 말한다.Dermis (陳皮) refers to the tangerine ( Cuntrus unshiu Markovich ) or mature rinds of related plants.
맥아는 보리에 물을 부어서 싹이 나게 한 다음에 말린 것이다.Malt pours water on barley to sprout and then dry.
당귀(학명: Angelica gigantis Nakai)는 승검초라고도 불리며, 보혈(補血)작용 및 활혈(活血)작용이 우수한 것으로 알려져 있다. Angelica gigantis Nakai (also known as Angelica gigantis Nakai ) is also known as Seunggeumcho, and is known to be excellent in blood and blood (補血) action.
산사는 산사나무(학명: Crataegus pinnatifida Bunge for. Pinnatifida)의 열매를 말린 것이다.Sansa is the fruit of the hawthorn ( Crataegus pinnatifida Bunge for.Pinnatifida ).
녹용은 꽃사슴·마록(馬鹿) 등 각종 숫사슴의 미골화(未骨化:아직 뼈로 굳어지지 않음)된 어린 뿔을 채취하여 가공한 약재를 말한다.Deer antler is a medicinal herb that has been harvested and processed into young horns, which have been coagulated (not yet hardened into bone) of various buckles, such as deer and maroc.
본 발명의 일 실시예에 따른 식품 조성물에서의 상술한 바와 같은 각각의 생 약 추출물은 예를 들어 생약의 원료 또는 이의 건조물을 각각 또는 혼합하여, 이들 중량의 약 5 내지 10배의 물을 가하고 70 내지 100 ℃ 에서 2 내지 12 시간동안 가열한 후 여과하고 그 여액을 감압 농축하는 열수 추출법이나 주정 추출법 등에 의해 얻어질 수 있다. 이때, 각 생약 추출물은 유효 성분을 최대한 추출할 수 있는 방법에 의한 것이라면 특별히 한정되지 않고, 다양한 추출법에 의해 얻어지는 추출물 형태일 수 있다. Each herbal extract as described above in the food composition according to an embodiment of the present invention is added to about 5 to 10 times the weight of each, for example by mixing each of the raw materials of the herbal medicine or its dried product or mixed with 70 It may be obtained by hot water extraction method, alcohol extraction method or the like, which is heated at 100 ° C. for 2 to 12 hours and then filtered and the filtrate is concentrated under reduced pressure. In this case, each herbal extract is not particularly limited as long as it is by a method capable of extracting the active ingredient as much as possible, and may be in the form of an extract obtained by various extraction methods.
특히, 본 발명의 일 실시예에 따른 식품 조성물에서의 녹용 추출물은 바실러스 속(Bacillus sp.) 균주로 발효시킨 발효물일 수 있다. 즉, 본 발명의 일 실시예에 따른 식품 조성물에서의 녹용 추출물은 예를 들어 녹용에 그 중량의 5 내지 10배의 물을 가하고 70 내지 100 ℃ 에서 2 내지 12시간 동안 가열한 후 여과하고 그 여액에 바실러스 속 균주를 첨가하여 예를 들어 약 25 내지 40 ℃ 에서 약 25 내지 40시간 동안 발효시킨 다음 여과하고, 그 여액을 감압 농축한 발효물일 수도 있으며, 녹용을 예를 들어 상술한 바와 같은 발효 방법으로 발효한 후, 이를 예를 들어 상술한 바와 같은 추출법을 통해 추출한 발효물일 수도 있다. 상술한 바와 같이 발효물 형태의 녹용의 경우, 발효하는 과정에서 미생물을 이용하여 녹용의 유효 성분 추출을 보다 용이하게 할 수 있으며, 유효 성분을 활성화 시킬 뿐만 아니라, 소화 흡수를 보다 용이하게 하여 체내에서 이용 효율을 높일 수 있다. In particular, the antler extract in the food composition according to an embodiment of the present invention may be a fermentation product fermented with Bacillus sp . That is, the antler extract in the food composition according to an embodiment of the present invention, for example, is added to the antler 5 to 10 times the weight of water and heated at 70 to 100 ℃ for 2 to 12 hours and then filtered and the filtrate The strain of the genus Bacillus to the fermentation, for example for about 25 to 40 hours at about 25 to 40 ℃ and then filtered, the filtrate may be a fermentation product concentrated under reduced pressure, for example, a fermentation method as described above for example antler After fermentation, it may be, for example, a fermented product extracted through the extraction method as described above. As described above, in the case of fermented antler, it is possible to more easily extract the active ingredient of the antler using microorganisms in the process of fermentation, not only to activate the active ingredient, but also to facilitate digestion and absorption in the body Use efficiency can be improved.
본 발명의 일 실시예에 따른 식품 조성물은 녹용 추출물 100중량부를 기준으로, 황기 추출물 10 내지 50중량부, 백출 추출물 5 내지 45중량부, 백복령 추출물 5 내지 45중량부, 진피 추출물 5 내지 45 중량부, 맥아 추출물 5 내지 45중량부, 당귀 추출물 5 내지 45중량부, 및 산사 추출물 5 내지 45중량부를 포함할 수 있고, 바람직하게는, 녹용 추출물 100 중량부를 기준으로, 황기 추출물 20 내지 40중량부, 백출 추출물 10 내지 30중량부, 백복령 추출물 10 내지 30중량부, 진피 추출물 10 내지 30중량부, 맥아 추출물 10 내지 30중량부, 당귀 추출물 10 내지 30중량부, 및 산사 추출물 10 내지 30중량부를 포함할 수 있다.Food composition according to an embodiment of the present invention, based on 100 parts by weight of the antler extract, 10 to 50 parts by weight of Astragalus extract, 5 to 45 parts by weight of white extract, 5 to 45 parts by weight of Baekbokyeong extract, 5 to 45 parts by weight of dermis extract 5 to 45 parts by weight of malt extract, Angelica extract 5 to 45 parts by weight, and 5 to 45 parts by weight of hawthorn extract, preferably, based on 100 parts by weight of deer antler extract, 20 to 40 parts by weight of Astragalus extract, 10 to 30 parts by weight of white extract, 10 to 30 parts by weight of Baekbokyeong extract, 10 to 30 parts by weight of dermis extract, 10 to 30 parts by weight of malt extract, 10 to 30 parts by weight of Angelica extract, and 10 to 30 parts by weight of hawthorn extract. Can be.
상술한 범위에 들도록 각 생약 추출물을 혼합함으로써 본 발명에서 목적하는 바와 같은 효과를 달성할 수 있는 식품 조성물을 수득할 수 있다.By mixing each herbal extract to fall within the above-mentioned range, a food composition capable of achieving the effect as desired in the present invention can be obtained.
또한, 본 발명의 식품 조성물은 필요에 따라 다양한 식품 첨가제를 추가로 포함할 수 있다.In addition, the food composition of the present invention may further include various food additives as needed.
본 발명의 일 실시예에 따른 식품 조성물은 특정 조합의 복합 생약추출물을 함유함으로써 뼈 길이를 성장시키고, 성장판 연골세포의 대사를 촉진하고, 성장인자인 IGF-1 및 BMP-2의 발현을 증가시키는 등 부작용 없이 우수한 성장 촉진 효과를 가져올 수 있어 특히 어린이 성장 촉진용 식품소재로서 유용하게 사용될 수 있다.Food composition according to an embodiment of the present invention contains a specific combination of complex herbal extracts to grow bone length, promote the metabolism of growth plate chondrocytes, increase the expression of growth factors IGF-1 and BMP-2 It can bring about an excellent growth promoting effect without side effects such as can be especially useful as a food material for promoting children's growth.
이하, 본 발명을 실시예에 의거하여 보다 구체적으로 설명한다. 단 하기 실시예는 본 발명을 예시하기 위한 것일 뿐, 본 발명의 범위가 이들로만 한정되는 것은 아니다.EMBODIMENT OF THE INVENTION Hereinafter, this invention is demonstrated more concretely based on an Example. However, the following examples are only for illustrating the present invention, and the scope of the present invention is not limited thereto.
[실시예 1] 복합 생약추출물의 제조 - (1)Example 1 Preparation of Complex Herbal Extract-(1)
황기, 백출, 백복령, 진피, 맥아, 당귀 및 산사를 각각 정선하고 세척하여 이물질을 제거한 후 건조시켰다. 건조된, 황기 26.67g, 백출 13.33g, 백복령 13.33g, 진피 13.33g, 맥아 13.33g, 당귀 10g 및 산사 10g을 추출기에 넣고 총 원료 중량의 약 5-10배의 물을 가한 다음 95℃에서 4시간 동안 가열하여 추출한 다음, 이 추출액을 1㎛ 카트리지 필터로 여과하고, 그 여액을 50℃ 이하로 유지하면서 50brix가 되도록 6시간 동안 감압 농축하여 황기, 백출, 백복령, 진피, 맥아, 당귀 및 산사의 혼합추출물을 얻었다.Astragalus, Baekchul, Baekbokryeong, Dermis, Malt, Angelica and Sansa were selected and washed to remove foreign substances and dried. Dried, Astragalus 26.67g, Baekchul 13.33g, Baekbokyeong 13.33g, Dermis 13.33g, Malt 13.33g, Angelica g 10g, and 10g Sansa were added to the extractor, and water was added at about 5-10 times the total weight of the raw material. After extracting by heating for a period of time, the extract was filtered with a 1 μm cartridge filter, and the filtrate was concentrated under reduced pressure for 6 hours while maintaining the filtrate at 50 ° C. or lower to 50brix. A mixed extract was obtained.
이어, 세척 및 건조된 녹용 100g을 분쇄하여 추출기에 넣고 녹용 중량의 약 5-10배의 물을 가한 다음 100℃에서 2시간 동안 가열하여 추출한 다음, 이 추출액을 1㎛ 카트리지 필터로 여과하고, 그 여액에 바실러스 속 균주를 첨가하고 37℃에서 30시간 동안 발효시킨 다음 0.25㎛ 필터를 이용하여 여과하고, 그 여액을 10brix가 되도록 감압 농축하여 녹용 발효추출물을 얻었다.Subsequently, 100 g of the washed and dried antler was crushed and placed in an extractor, and water was added at about 5-10 times the weight of the antler, followed by heating at 100 ° C. for 2 hours, followed by filtering the extract with a 1 μm cartridge filter. Bacillus strains were added to the filtrate, fermented at 37 ° C. for 30 hours, filtered using a 0.25 μm filter, and the filtrate was concentrated under reduced pressure to 10brix to obtain a antler fermentation extract.
상기에서 얻은 혼합추출물 및 녹용 발효추출물을 1:1의 중량비로 혼합하여 복합 생약추출물을 제조하였다. The mixed extract and antler fermentation extract obtained in the above was mixed in a weight ratio of 1: 1 to prepare a composite herbal extract.
[실시예 2] 복합 생약추출물의 제조 - (2)Example 2 Preparation of Complex Herbal Extract-(2)
황기, 백출, 백복령, 진피, 맥아, 당귀 및 산사를 각각 별도로 추출한 후 혼합하는 것을 제외하고는 상기 실시예 1과 동일한 방법으로 복합 생약추출물을 제조하였다. 이때, 황기, 백출, 백복령, 진피, 맥아, 당귀 및 산사 추출물, 및 녹용 발효추출물은 약 0.268:0.133:0.133:0.133:0.133:0.1:0.1:1의 비율로 혼합하였다.A crude herbal extract was prepared in the same manner as in Example 1, except that Astragalus, Baekchul, Baekbokyeong, Dermis, Malt, Angelica and Sansa were separately extracted and mixed. At this time, Astragalus, Baekchul, Baekbokryeong, Dermis, Malt, Angelica and Sansa extract, and antler fermentation extracts were mixed at a ratio of about 0.268: 0.133: 0.133: 0.133: 0.133: 0.1: 0.1: 1.
[시험예] 시료 투여 및 실험군 설정[Test Example] Sample administration and experimental group setting
SD계 랫트를 각 군당 10∼12마리씩 무작위로 나눈 후, 정상식이군(대조군), 생약추출물(한방추출물) 저농도군과 고농도군을 설정하여 흰쥐의 성장률이 가장 큰 생후 25일(실험 개시일)부터 5일간 매일 각 시료를 사료에 첨가하여 경구 투여하였다. 대조군의 경우는 증류수를 경구 투여하였고, 한방추출물 투여군의 경우는 상기 실시예 1에서 제조한 복합 한방추출물을 80 mg/kg(저농도군)과 400 mg/kg(고농도군)의 농도로 나누어 경구 투여하였다.SD rats were randomly divided into 10-12 rats in each group, and then the normal diet group (control group), herbal extract (herbal extract) and low concentration group and high concentration group were set up. Each sample was added orally to the feed daily. In the case of the control group, distilled water was orally administered, and in the case of the herbal extract administration group, the complex herbal extract prepared in Example 1 was divided orally into 80 mg / kg (low concentration group) and 400 mg / kg (high concentration group). It was.
[시험예 1] 랫트의 체중 변화 Test Example 1 Weight Change of Rat
실험 개시일부터 종료일까지 매일 같은 시각 체중을 측정하였다. 체중 데이터는 전반적인 대사 및 성장의 지표로서 활용된다. 투여 전 각 동물은 92±2g의 랫트로 고른 체중범위를 나타내었다. 정상식이군, 한방추출물 저농도군과 고농도군 각각의 랫트의 경시적인 체중 변화를 도 1에 나타내었다. 그 결과, 시험물질 투여기간 중 정상식이군 및 한방추출물 투여군 모두 성장에 따른 꾸준한 체중증가를 보였으며, 각각의 실험군 간에 체중의 통계적 유의 차는 없는 것으로 나타났다.The same visual weight was measured every day from the start of the experiment to the end of the experiment. Weight data is used as an indicator of overall metabolism and growth. Before administration, each animal had a weight range of 92 ± 2 g in rats. The weight change of the rats of the normal diet group, herbal extract low concentration group and high concentration group, respectively, is shown in FIG. 1. As a result, the normal diet group and the herbal extract group showed steady weight gain with growth during the administration period of the test substance, and there was no statistically significant difference in body weight between the experimental groups.
[시험예 2] 장골 길이성장에 대한 효과Test Example 2 Effect on Iliac Length Growth
흰쥐의 골성장에 대한 한방추출물의 효능을 측정하기 위해, 한쓴(Hansson)이 처음 시도한 방법을 사용하였다. 이는 정상적인 골대사를 관찰하기 위한 방법으로 형광인자가 칼슘과 킬레이트 결합을 통해 골에 침착되는 현상을 이용한 것이다. 골 생성이 가장 활발한 성장기에 형광인자를 투여하면, 투여된 형광인자는 골성장판 하부의 골신생부에 가장 많이 침착하여 선을 형성하므로, 이를 이용하여 1회 투여한 후 일정기간 후에 형광선과 성장판 사이의 길이를 형광현미경으로 관찰하여 성장한 길이를 측정하였다. 모든 실험군에 똑같이 실험개시 후 4일째에 형광인자로서 칼세인 (calcein: 10 mg/kg, i.p.: Sigma, U.S.A.)을 투여하였다. To measure the efficacy of herbal extracts on bone growth in rats, Hansson's first attempt was used. This is a method for observing normal bone metabolism by using the phenomenon that the fluorescent factor is deposited on the bone through calcium and chelate bonds. When the fluorescent factor is administered in the growth stage where bone formation is most active, the administered fluorescent factor is most deposited on the bone neoplasia at the lower part of the bone growth plate to form lines. The length of the growth was observed by fluorescence microscopy. In all experimental groups, calcein (calcein: 10 mg / kg, i.p .: Sigma, U.S.A.) was administered as a fluorescent factor 4 days after the start of the experiment.
형광인자 투여 1일 후에 흰쥐를 해부하였다. 흰쥐의 좌우 족경골(tibia)을 떼어내어 2시간 동안 0.1 M 인산염-완충화된 포르말린(phosphate-buffered formalin) 고정액에 고정시킨 다음, 탈회시켜 2-3일 동안 방치한 후, 동결에 대한 보호를 위해 30% 수크로즈(sucrose)에 담가 4℃에서 하룻밤동안 유지하였다. 고정된 골조직을 동결한 후 슬라이딩 마이크로톰(sliding microtome)(HM440E, Zeiss, Germany)을 사용하여 족경골(tibia) 근위부(proximal part)의 시상절편(sagital section)을 매 60 μm씩 수집하였다. 수집한 절편을 슬라이드 글라스 위에 놓고 건조한 후 형광현미경을 이용하여 골조직 내 형광인자의 침착으로 형성된 선과 성장판 사이의 길이를 측정하여, 측정된 랫트의 장골 길이성장 정도를 도 2에 나타내었다. Rats were dissected 1 day after fluorescein administration. The left and right tibia of the rats were removed and fixed in 0.1 M phosphate-buffered formalin fixative for 2 hours, then demineralized and left for 2-3 days, then protected against freezing. Soaked in 30% sucrose and kept overnight at 4 ° C. After freezing the fixed bone tissue, a sagittal section of the tibia proximal part was collected every 60 μm using a sliding microtome (HM440E, Zeiss, Germany). The collected sections were placed on a slide glass and dried, and then the length between the growth plate and the growth plate formed by the deposition of fluorescent factors in bone tissue was measured using a fluorescence microscope.
도 2로부터 알 수 있듯이, 대조군은 379.4 ± 7.6 μm, 한방추출물 고농도(400 mg/kg) 투여군은 426.5 ± 11.2 μm, 한방추출물 저농도(80 mg/kg) 투여군은 402.2 ± 7.5 μm의 길이성장을 나타내어, 한방추출물 투여군이 대조군에 비해 길이성장 촉진효과가 우수하였으며, 한방추출물 고농도군이 통계적인 유의성을 보였다(p<0.05).As can be seen from Figure 2, the control group 379.4 ± 7.6 μm, the herbal extract high concentration (400 mg / kg) administration group 426.5 ± 11.2 μm, the herbal extract low concentration (80 mg / kg) administration group shows a growth of 402.2 ± 7.5 μm In addition, the herbal extract-treated group had better length-promoting effect than the control group, and the high herbal extract group showed statistical significance (p <0.05).
[시험예 3] 성장판 연골세포 대사에 미치는 영향Test Example 3 Effect on Growth Plate Chondrocyte Metabolism
상기와 같이 매 60 μm씩 수집한 절편을 슬라이드 글라스 위에 놓고 건조한 후 크레실바이올렛(cresyl violet) 염색한 다음 성장판의 높이를 측정하였다. 측정된 랫트의 성장판의 높이 변화를 도 3에 나타내었다. As described above, every 60 μm collected sections were placed on a slide glass, dried, and stained with cresyl violet, and then the height of the growth plate was measured. The height change of the growth plate of the rat is shown in FIG. 3.
도 3으로부터 알 수 있듯이, 성장판의 높이는 대조군의 경우 552.3 ± 9.3 μm이었고, 한방추출물(400 및 80 mg/kg) 투여군의 경우 각각 613.0 ± 9.6 μm 및 604.9 ± 8.9 μm이었다.As can be seen from Figure 3, the growth plate height was 552.3 ± 9.3 μm for the control group, 613.0 ± 9.6 μm and 604.9 ± 8.9 μm for the herbal extract (400 and 80 mg / kg) administration group, respectively.
또한, 성장판의 형광현미경 사진을 도 4에 나타내었는데, A사진은 대조군의 성장판 사진이고, B사진은 한방추출물 고농도군의 성장판 사진이다. 성장판은 골조직을 폭발적으로 생성하는 특수한 조직으로 유소아, 청소년기까지만 가지고 있는 성장에 필수적인 조직이다. 따라서 성장이 촉진되려면 성장판의 기능이 촉진되어야 하며, 이에 수반되어 성장판의 구조 또한 증식되어 성장판의 크기가 늘어나게 된다. A사진의 위 화살표에는 성장판 연골세포가 증식되기를 기다리고 있는 휴지기의 성장판 연골세포가 있고, 그 아래에는 납작한 핵이 여러 개 뭉쳐져 있는 모양의 증식부의 성장판 연골세포가 보인다. 그 아래에는 성장판 연골세포가 2-5배 정도 커져 있는 모습을 볼 수 있는데 이 부위가 비대부이다. 이 아래 부위에서 아래 화살표 부위까지가 연골세포 안에 골주(뼈대)가 형성되어 골화되는 골화부이다. 이 부분에서 골이 형성되고 이후 연골세포가 세포자연사과정을 거쳐 제거되고 나면 뼈만 남게 되어 골성장이 완료되게 된다. 즉 골 길이성장은 전적으로 성장판의 기능에 달려있다. 도 4의 사진에서 보는 바와 같이, 본 발명에 따른 한방추출물 투여시(B의 경우) 성장판 내 연골세포의 증식으로 A의 경우에 비해 성장판 경계부가 높아진 것을 알 수 있다.In addition, the fluorescence microscope picture of the growth plate is shown in Figure 4, A picture is the growth plate picture of the control group, B picture is the growth plate picture of the herbal extract high concentration group. Growth plate is a special tissue that explosively produces bone tissue, which is essential for growth only in infants and adolescents. Therefore, in order for growth to be promoted, the function of the growth plate should be promoted, and along with this, the structure of the growth plate is also multiplied to increase the size of the growth plate. In the upper arrow of the photograph A, there is a growth plate chondrocyte in the resting phase waiting for the growth plate chondrocytes to proliferate, and below it, the growth plate chondrocytes of the proliferative part in which the flat nucleus is clustered together are shown. Below it, the growth plate cartilage cells can be seen 2-5 times larger, which is the hypertrophy. From the lower part to the lower part of the arrow is a osteoporosis (oskeleton) is formed in the chondrocytes ossified bone. In this part, bone is formed, and after chondrocytes are removed through cellular natural death process, only bone remains and bone growth is completed. Bone length growth depends entirely on the function of the growth plate. As shown in the photograph of Figure 4, it can be seen that when the herbal extract according to the present invention (in case of B) the growth plate border is increased compared to the case of A by the proliferation of chondrocytes in the growth plate.
[시험예 4] 성장판 내 IGF-1 (인슐린양 성장인자(insulin-like growth factor)-1) 발현에 미치는 영향[Test Example 4] Effect on the expression of IGF-1 (insulin-like growth factor-1) in the growth plate
슬라이딩 마이크로톰(HM440E, Zeiss, Germany)을 사용하여 족경골 근위부의 시상절편을 매 40 μm씩 수집하였다. 면역 염색을 위해, 1차 항체로는 IGF-1 항체(Santa Cruz Biotech, U.S.A.)를, 2차 항체로는 항-염소(anti-goat) 항체(Vector Lab, U.S.A.)를 각각 사용하였고, 벡타스테인 엘라이트 에이비씨 키트(Vectastain elite ABC kit)(Vector Lab, U.S.A.)를 사용하였다.Sagittal sections proximal the tibia were collected every 40 μm using a sliding microtom (HM440E, Zeiss, Germany). For immunostaining, IGF-1 antibody (Santa Cruz Biotech, USA) was used as the primary antibody and anti-goat antibody (Vector Lab, USA) was used as the secondary antibody, respectively. Vectastain elite ABC kit (Vector Lab, USA) was used.
구체적으로, 조직 절편들을 0.1 M PBS (인산염-완충화된 식염수(phospate-buffered saline), pH 7.2)에 5분 동안 담그고, 트리톤(Triton)-X 100용액 (Sigma, U.S.A.)에서 15분간 2회, 0.1 M PBS + 0.5% BSA (소혈청알부민(Bovine Serum Albumin), Sigma, U.S.A.)에서 15분간 2회 씻어낸 다음, 1차 항체와 함께 상온에서 하룻밤 동안 반응시켰다. 다음날 0.1 M PBS + 0.5% BSA에서 15분간 2회 헹군 다음 그 절편을 2차 항체와 함께 60분간 반응시키고, 다시 0.1 M PBS + 0.5% BSA로 15분간 2회 헹군 후, ABC(아비딘-비오틴-퍼옥시데이즈(avidin-biotin-peroxidase)) 복합체를 1:50의 농도로 첨가하여 상온에서 60분 동안 반응시켰다. 각 조직절편들을 0.1M PBS로 15분간 2회 세척한 다음, 최종적으로 0.05%의 DAB (3.3-다이아미노벤지 딘(3,3-diaminobenzidine), Sigma, U.S.A.) 및 0.03% 과산화수소가 포함된 0.1M PBS와 반응시켰다. 발색된 후 새 0.1 M PBS에 각 조직절편을 넣어 반응을 중지한 뒤 슬라이드 표본으로 제작하여 관찰하였다.Specifically, the tissue sections were soaked in 0.1 M PBS (phosphate-buffered saline, pH 7.2) for 5 minutes and twice in Triton-
랫트 조직절편의 형광현미경 사진을 도 5에 나타내었는데, 왼쪽(a, b, c, d)은 대조군의 사진이고, 오른쪽(e, f, g, h)은 한방추출물 고농도군의 사진이다. IGF-1의 성장판 조직 내 발현을 대조군과 한방추출물 투여군에서 비교해보았을 때, 대조군과 투여군 모두 휴지부 (a 및 e)와 증식부 (b 및 f)에선 IGF-1 발현이 약하게 나타났으나, 비대부 (c 및 g)와 골화부 (d 및 h)에선 한방추출물 투여군에서 면역염색이 증가하여 IGF-1 발현이 보다 증가하였음을 관찰할 수 있었다. The fluorescence micrograph of the rat tissue section is shown in Figure 5, the left (a, b, c, d) is a picture of the control group, the right (e, f, g, h) is a photograph of a high concentration of herbal extracts. When the expression of IGF-1 in the growth plate tissue was compared between the control group and the herbal extract group, the IGF-1 expression was weakly expressed in the resting part (a and e) and the proliferating part (b and f) in both the control group and the administration group. In (c and g) and ossification (d and h), the immunostaining was increased in the herbal extract-administered group.
[시험예 5] 성장판 내 BMP-2 (골 형태형성인자(bone morphogenic protein)-2) 발현에 미치는 영향[Test Example 5] Effect on the expression of BMP-2 (bone morphogenic protein-2) in growth plate
상기 시험예 4에서와 동일한 방법으로 관찰하였으며, 면역 염색에 사용된 1차 항체로는 BMP-2 항체(Santa Cruz Biotech, U.S.A.)를 사용하였고, 2차 항체로는 항-염소 항체(Vector Lab, U.S.A.)를 사용하였다.Observation was carried out in the same manner as in Test Example 4, and the primary antibody used for immunostaining was BMP-2 antibody (Santa Cruz Biotech, USA), and the secondary antibody was anti-chlorine antibody (Vector Lab, USA).
랫트 조직절편의 형광현미경 사진을 도 6에 나타내었는데, 왼쪽(a, b, c, d)은 대조군의 사진이고, 오른쪽(e, f, g, h)은 한방추출물 고농도군의 사진이다. BMP-2의 성장판 조직 내 발현을 대조군과 한방추출물 투여군에서 비교해보았을 때, 대조군과 투여군 모두 휴지부 (a 및 e)와 증식부 (b 및 f)에선 BMP-2 발현이 약하게 나타났으나, 비대부 (c 및 g)와 골화부 (d 및 h)에선 한방추출물 투여군에서 면 역염색이 증가하여 BMP-2 발현이 보다 증가하였음을 관찰할 수 있었다.The fluorescence micrograph of the rat tissue section is shown in Figure 6, the left (a, b, c, d) is a picture of the control group, the right (e, f, g, h) is a photograph of a high concentration of herbal extracts. When the expression of BMP-2 in the growth plate tissue was compared between the control group and the herbal extract group, BMP-2 expression was weakly expressed in the resting part (a and e) and the proliferating part (b and f) in both the control group and the administration group. In (c and g) and ossification (d and h) it was observed that the BMP-2 expression was increased due to increased immunostaining in the herbal extract group.
도 1은 시험예 1에서 측정한 랫트의 5일 간의 경시적인 체중 변화 그래프이다.1 is a graph of weight change over time for 5 days of rats measured in Test Example 1.
도 2는 시험예 2에서 측정한 랫트의 장골 길이성장 정도를 나타낸 그래프이다.2 is a graph showing the degree of long bone growth of rats measured in Test Example 2.
도 3은 시험예 3에서 측정한 랫트의 성장판의 높이 변화를 나타낸 그래프이다.3 is a graph showing the change in height of the growth plate of the rat measured in Test Example 3.
도 4는 시험예 3에서 관찰한 랫트 성장판의 형광현미경 사진으로서, A사진은 대조군의 사진이고, B사진은 한방추출물 고농도군의 사진이다.Figure 4 is a fluorescence microscope picture of the rat growth plate observed in Test Example 3, A picture is a picture of the control group, B picture is a photograph of the high concentration group of herbal extracts.
도 5는 랫트 성장판 내 IGF-1 발현 정도를 측정하기 위해 시험예 4에서 관찰한 조직절편의 형광현미경 사진으로서, 왼쪽(a, b, c, d)은 대조군의 사진이고, 오른쪽(e, f, g, h)은 한방추출물 고농도군의 사진이다.5 is a fluorescence micrograph of tissue sections observed in Test Example 4 to measure the degree of IGF-1 expression in rat growth plate, the left (a, b, c, d) is a picture of the control, the right (e, f , g, h) is a photograph of the high concentration group of herbal extracts.
도 6은 랫트 성장판 내 BMP-2 발현 정도를 측정하기 위해 시험예 5에서 관찰한 조직절편의 형광현미경 사진으로서, 왼쪽(a, b, c, d)은 대조군의 사진이고, 오른쪽(e, f, g, h)은 한방추출물 고농도군의 사진이다.6 is a fluorescence micrograph of tissue sections observed in Test Example 5 to measure the degree of BMP-2 expression in the rat growth plate, the left (a, b, c, d) is a picture of the control, the right (e, f , g, h) is a photograph of the high concentration group of herbal extracts.
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090009842A KR20100090514A (en) | 2009-02-06 | 2009-02-06 | Food composition for accelerating the growth |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090009842A KR20100090514A (en) | 2009-02-06 | 2009-02-06 | Food composition for accelerating the growth |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20100090514A true KR20100090514A (en) | 2010-08-16 |
Family
ID=42756072
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020090009842A KR20100090514A (en) | 2009-02-06 | 2009-02-06 | Food composition for accelerating the growth |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20100090514A (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013058594A2 (en) * | 2011-10-20 | 2013-04-25 | (주)메레데코리아 | Method for preparing a fermented deer antler extract having an anti-inflammatory activity, extract obtained by the method and use of such extract |
KR20150060572A (en) | 2013-11-25 | 2015-06-03 | 경희대학교 산학협력단 | Composition for Preventing or Treating Short Stature Comprising Hordeum vulgare Extract |
CN104856053A (en) * | 2015-04-30 | 2015-08-26 | 重庆市康泽科技开发有限责任公司 | Braised deer meat rib and making method thereof |
CN111812333A (en) * | 2020-06-29 | 2020-10-23 | 吉林省东北亚生物科技有限公司 | Method for comparing activity of ligamentum cervi natural peptide and enzymatic hydrolysis peptide on resisting rheumatoid arthritis |
KR102189949B1 (en) * | 2019-10-29 | 2020-12-11 | 김득수 | Process for producing fermented antler antagonistic tee and fermented antler antagonistic tee produced by using same |
KR102218990B1 (en) * | 2019-10-29 | 2021-02-22 | 김득수 | Process for producing fermented antler antagonistic tee and fermented antler antagonistic tee produced by using same |
KR102218991B1 (en) * | 2019-10-29 | 2021-02-22 | 김득수 | Process for producing fermented antler antagonistic tee and fermented antler antagonistic tee produced by using same |
KR102233135B1 (en) * | 2019-10-29 | 2021-03-26 | 김득수 | Process for producing fermented antler antagonistic tee and fermented antler antagonistic tee produced by using same |
CN115152895A (en) * | 2022-06-13 | 2022-10-11 | 江苏护理职业学院 | Fermented astragalus membranaceus compound feed additive capable of promoting growth and resisting oxidation |
-
2009
- 2009-02-06 KR KR1020090009842A patent/KR20100090514A/en not_active Application Discontinuation
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104105492B (en) * | 2011-10-20 | 2017-12-05 | 株式会社美莱德可利亚 | The purposes of the fermentation preparation method of deer antler extract, thus obtained extract and the extract with anti-inflammatory activity |
WO2013058594A3 (en) * | 2011-10-20 | 2013-06-20 | (주)메레데코리아 | Method for preparing a fermented deer antler extract having an anti-inflammatory activity, extract obtained by the method and use of such extract |
CN104105492A (en) * | 2011-10-20 | 2014-10-15 | 株式会社美莱德可利亚 | Method for preparing fermented deer antler extract having anti-inflammatory activity, extract obtained by the method and use of such extract |
WO2013058594A2 (en) * | 2011-10-20 | 2013-04-25 | (주)메레데코리아 | Method for preparing a fermented deer antler extract having an anti-inflammatory activity, extract obtained by the method and use of such extract |
KR20150060572A (en) | 2013-11-25 | 2015-06-03 | 경희대학교 산학협력단 | Composition for Preventing or Treating Short Stature Comprising Hordeum vulgare Extract |
JP2016539943A (en) * | 2013-11-25 | 2016-12-22 | ユニヴァーシティ−インダストリー コーオペレイション グループ オブ キュン ヒー ユニヴァーシティ | Composition for preventing or treating growth disorders containing malt extract |
US11324795B2 (en) | 2013-11-25 | 2022-05-10 | University-Industry Cooperation Group Of Kyung Hee University | Composition comprising Hordeum vulgare extract for preventing or treating short stature |
CN104856053A (en) * | 2015-04-30 | 2015-08-26 | 重庆市康泽科技开发有限责任公司 | Braised deer meat rib and making method thereof |
KR102189949B1 (en) * | 2019-10-29 | 2020-12-11 | 김득수 | Process for producing fermented antler antagonistic tee and fermented antler antagonistic tee produced by using same |
KR102218990B1 (en) * | 2019-10-29 | 2021-02-22 | 김득수 | Process for producing fermented antler antagonistic tee and fermented antler antagonistic tee produced by using same |
KR102218991B1 (en) * | 2019-10-29 | 2021-02-22 | 김득수 | Process for producing fermented antler antagonistic tee and fermented antler antagonistic tee produced by using same |
KR102233135B1 (en) * | 2019-10-29 | 2021-03-26 | 김득수 | Process for producing fermented antler antagonistic tee and fermented antler antagonistic tee produced by using same |
CN111812333A (en) * | 2020-06-29 | 2020-10-23 | 吉林省东北亚生物科技有限公司 | Method for comparing activity of ligamentum cervi natural peptide and enzymatic hydrolysis peptide on resisting rheumatoid arthritis |
CN115152895A (en) * | 2022-06-13 | 2022-10-11 | 江苏护理职业学院 | Fermented astragalus membranaceus compound feed additive capable of promoting growth and resisting oxidation |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20100090514A (en) | Food composition for accelerating the growth | |
JP3502374B2 (en) | Extracts derived from Pueraria mirifica, Butea Superba and / or Mukna Koretch and methods for extracting the same | |
CN105104641A (en) | Preparing method for semen euryales and chrysanthemum instant tea with high blood pressure, lipid and glucose reducing effect | |
JP7471393B2 (en) | Tea composition having preventive or ameliorative effects on respiratory diseases and pharmaceutical composition containing the same | |
KR101855821B1 (en) | Composition for relieving of menopausal symptoms and improving blood circulation | |
AU2014284932B2 (en) | Pharmaceutical composition for promoting bone tissue formation, containing Stauntonia hexaphylla leaf extract as active ingredient | |
KR100760670B1 (en) | The manufacture method of nature pack composition having whitening effect | |
CN104284601B (en) | Secrete for promoting insulin-like growth factor and the white radix-polygoni multiflori extract of bone growth and Radix Dipsaci extract and manufacture method thereof | |
KR101661688B1 (en) | Composition for preventing, improving or treating atopic dermatitis comprising natural extracts | |
CN103126970B (en) | For Anti-hair loss or trichogenous composition | |
KR100787639B1 (en) | The composition for natural hair growth promoting agents | |
CN103749821A (en) | Gynostemma pentaphyllum health-care tea capable of enhancing immunity and preparation method thereof | |
CN103550129B (en) | Plant composite polysaccharide, Preparation Method And The Use | |
KR20030079604A (en) | The composition of improved materials in treating alcohol hangover and boosting an energy. | |
CN107812115A (en) | A kind of Chinese medicine composition for treating diabetes | |
KR100787640B1 (en) | The composition for natural hair growth promoting agents | |
CN108310015B (en) | Combination of umbilical cord mesenchymal stem cells for treating hyperglycemia and diabetic nephropathy | |
CN108210518B (en) | Combination of umbilical cord mesenchymal stem cells for treating hyperglycemia and diabetic nephropathy | |
CN108324737B (en) | Combination of umbilical cord mesenchymal stem cells for treating hyperglycemia and diabetic nephropathy | |
CN104800344A (en) | Traditional Chinese medicine preparation for treating tinea unguium and preparation method of traditional Chinese medicine preparation | |
KR102168531B1 (en) | Cosmetic composition for enhancing skin elasticity or improving skin wrinkle containing herb extracts | |
KR20200062453A (en) | Herbal medicinal compositions for maintaining bone and muscle health, including meal worm, and method for producing the same | |
KR20230018906A (en) | Composition for Bone Growth Promoting comprising Complex Extract of Cyanchum wilfordii and Phlomis umbrosa and Health Functional Food containing the same | |
CN109568496B (en) | Detection method of traditional Chinese medicine composition for treating diabetes | |
KR101147288B1 (en) | Oral hair growth composition from medical plant extracts and process for preparing thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application |